Should psychedelics be used for therapy? Psychiatrists think so
Fox8, September 22, 2023
In 2016, only about 43% of doctors agreed that psychedelics such as LSD, Psilocybin and other similar medicines could help with psychiatric disorders. But just seven years later, more than 80% of those surveyed feel that the medical use of these medicines could help.
Success of MDMA in PTSD Study Could Pave the Way for U.S. Approval of the Psychedelic
Time, September 15, 2023
“It’s the first innovation in PTSD treatment in more than two decades. And it’s significant because I think it will also open up other innovation,” said Amy Emerson, CEO of MAPS Public Benefit Corporation, the research sponsor.
The firms hoping to take psychedelic drugs mainstream
BBC, September 15, 2023
This July in Bend, Oregon, Josh Goldstein facilitated one of the first psilocybin sessions under the state’s new regulatory framework for people to access psilocybin.
MDMA Therapy Inches Closer to Approval
New York Times, September 14, 2023
Results of a new study may offer regulators enough evidence to allow MDMA to be considered for use as a PTSD treatment.
Could psychedelic trips inspire faster climate action?
Raconteur, September 5, 2023
A growing body of research suggests that psychedelic experiences could improve our connectedness to nature and inspire faster action on the climate crisis.
Magic mushrooms could treat depression, anxiety and PTSD, researchers claim
NY Post, September 1, 2023
The Journal of the American Medical Association published an investigation into the use of psilocybin mushrooms to treat major depressive disorder (MDD). In some cases, MDD doesn’t respond to such treatments as medication or psychotherapy. But a growing body of evidence suggests that psilocybin, the active ingredient in “magic” mushrooms, can help with depression and other conditions, such as anxiety and post-traumatic stress disorder.
How taking MDMA with your partner could boost your relationship
Financial Review, August 18, 2023
An Australian team hopes to become the first researchers to measure the outcome of using MDMA to help couples in conflict.
MDMA and magic mushrooms have arrived: psychedelic trip to new therapies
Herald Sun, July 24, 2023
MDMA and psilocybin can now be used clinically in Australia. Here’s a look at what that means, how we came to this point and the ASX stocks involved.
Psychedelics show promise for treating anorexia in early trials
New Scientist, July 24, 2023
Small studies suggest that psilocybin may reduce the severity of eating disorders and increase people’s motivation to recover from the condition.
Australia Legalizes Psychedelics: Are the US and Canada Next?
Microdose.Buzz, July 11, 2023
Last week, we received monumental psychedelic news out of Australia. There, regulators decided to allow psilocybin-assisted therapy to treat depression, and MDMA-assisted therapy to treat PTSD (with diagnosis and a prescription).
TV star went from ‘a journey through the gates of hell’ to hosting psychedelic trips for changemakers
Forbes, July 6, 2023
How a Shark Tank shark was inundated with requests from fellow business leaders to take them to the Amazon and make them one with everything. MMA Advisory member, Dr Catriona Wallace tells her story.
MDMA: Australia begins world-first psychedelic therapy
BBC News, July 1, 2023
Professor David Nutt, Head of Neuropsychopharmacology at the UK’s Imperial College, congratulated Australia on “leading the world in this vital treatment innovation”.
Psychedelic researcher and psychiatrist Dr Ben Sessa described the approval as pioneering. “This is where the global psychedelic spotlight now shines,” he told the BBC.
Australia Approves Psilocybin And MDMA For Therapeutic Use
Forbes, June 30, 2023
“Australia is creating an interesting model that could pave the way forward for the rest of the world,” Dr. Michael Alpert, a psychiatrist at Harvard Medical School, told ABC News.
Meet the Psychedelic Boom’s First Responders
WIRED, June 29, 2023
A new movement of volunteers will guide you through your psychedelic experience.
Psychedelic-assisted therapy is now legal in Australia
BODY+SOUL, June 29, 2023
The use of psychedelics for the treatment of mental health conditions has been legalised in Australia, but how will it work exactly? Psychedelics are set to be the future of mental health treatments, and this week, they’ll be legally available for use in psychotherapy. As of July 1, psilocybin and MDMA will be available for medicinal use in Australia, making us the first country in the world to do so.
Qld allows use of MDMA, psilocybin to treat mental illness
Courier Mail, June 16, 2023
Queensland mental health patients will have access to psychedelic medicines within weeks after the government quietly changed regulations. Read the full PDF article here.
The Psychedelic Scientist Who Sends Brains Back to Childhood
Wired, June 15, 2023
Kids soak up new skills, adults not so much. But neuroscientist Gül Dölen might have found a way—with medicine—to help grownups learn like little ones.
Aussie psychedelics stocks aim to carve slice out of global market ‘worth $63 billion’
The Daily Telegraph, April 28, 2023
Australia’s psychedelics market could be worth $2 billion, a business leader claims, as five ASX stocks prepare for seismic changes in the industry.
The big idea: should doctors be able to prescribe psychedelics?
The Guardian, April 10, 2023
A move to allow Australian psychiatrists to treat depression with psilocybin may herald a new era
MAPS PBC Announces Positive Topline Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for Treatment of PTSD
MAPS Public Benefit Corporation, April 6, 2023
MAPS Public Benefit Corporation (“MAPS PBC”), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced positive topline results from an observational follow-up study evaluating the long-term safety and efficacy of MDMA-assisted therapy for post–traumatic stress disorder (“PTSD”). Preliminary findings show that participants in this study demonstrated a durable response at least six months, and in some cases a year or more, after their final MDMA-assisted therapy session during the Phase 3 study.